{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-030493","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.738762+00:00","generated_at":"2026-06-08T17:02:38.250823+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clene Q3 net loss narrows to $2.4M; ALS drug shows survival benefit, receives $45.1M NIH grant","bullets":["Net loss $2.4M ($0.02/sh) vs $11.0M ($0.17/sh) in Q3 2022; R&D expense $6.0M.","Cash $42.1M as of Sep 30, 2023, expected to fund operations into Q3 2024.","CNM-Au8 in ALS: 19.3-month median survival benefit in RESCUE-ALS OLE; 49% decreased death risk in HEALEY vs PRO-ACT historical controls.","Awarded $45.1M NINDS/NIH grant for expanded access of CNM-Au8 in ALS.","FDA regulatory discussion planned for Q4 2023 to accelerate ALS submission path."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-030493","json":"https://secwatch.observer/filing/0001437749-23-030493.json","markdown":"https://secwatch.observer/filing/0001437749-23-030493.md","text":"https://secwatch.observer/filing/0001437749-23-030493.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923030493/0001437749-23-030493-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923030493/clnn20230829_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T17:02:38.250823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e7a26f21f37375c3522bd501f7f82c810839f35","claim":"Clene Inc. reported third quarter 2023 results: net income $2.4 million, EPS $0.02 per share.","evidence_excerpt":"Clene reported a net loss of $2.4 million, or $0.02 per share, for the quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923030493/0001437749-23-030493-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Net income","value":"$2.4 million"},{"label":"EPS","value":"$0.02 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}